Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FCRE1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $78,961
Award facts
- Contract value 100% obligated
- $78,961.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $78,961 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. This firm fixed-price delivery order, issued on October 21, 2025, with an ultimate completion date of November 12, 2025, was awarded without a set-aside designation, reflecting DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The award falls under the company's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to ensure reliable pharmaceutical supply chains for Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group holds a single-award IDC designated SPE2DR under the PPV-G GEN V program with a $499.999 billion ceiling value and completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. The company's established performance on numerous delivery orders for diverse pharmaceutical products—including specialty biologics, oncology treatments, vaccines, and medical consumables—demonstrates its capacity to fulfill the specialized pharmaceutical requirements of the federal military medical system globally. This delivery order for XOLAIR, a biologic immunosuppressant agent, exemplifies the types of specialized pharmaceutical products DMS Pharmaceutical Group routinely supplies to support Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FCRE1?
SPE2DR26FCRE1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 21, 2025.
How much is contract SPE2DR26FCRE1 worth?
The government has obligated $78,961 on SPE2DR26FCRE1.
Is contract SPE2DR26FCRE1 an order under another contract?
Yes. SPE2DR26FCRE1 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRE1 competed?
The extent of competition for SPE2DR26FCRE1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award